Prodrugs of DP IV-inhibitors

Details Prodrugs of DP IV-inhibitors Prodrugs of DP IV-inhibitors

2007-01-23

2007-01-23

Chism, B. Dell (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S019300, C530S330000

Reexamination Certificate

active

10735582

ABSTRACT:
Prodrug compounds of unstable inhibitors of the serine peptidase dipeptidyl peptidase IV, are used in the treatment of various disorders, especially of metabolic disorders. The Prodrug compounds can be used in the treatment of impaired glucose tolerance, glucosuria, hyperlipidaemia, metabolic acidoses, diabetes mellitus, diabetic neuropathy and nephropathy.

REFERENCES:
patent: 2961377 (1960-11-01), Shapiro et al.
patent: 3174901 (1965-03-01), Sterne
patent: 3879541 (1975-04-01), Kabbe et al.
patent: 3960949 (1976-06-01), Ahrens et al.
patent: 4028402 (1977-06-01), Fischer et al.
patent: 4935493 (1990-06-01), Bachovchin et al.
patent: 5433955 (1995-07-01), Bredehorst et al.
patent: 5462928 (1995-10-01), Bachovchin et al.
patent: 5512549 (1996-04-01), Chen et al.
patent: 5543396 (1996-08-01), Powers et al.
patent: 5614379 (1997-03-01), MacKellar
patent: 5624894 (1997-04-01), Bodor
patent: 5705483 (1998-01-01), Galloway et al.
patent: 5827898 (1998-10-01), Khandwala et al.
patent: 5939560 (1999-08-01), Jenkins et al.
patent: 6006753 (1999-12-01), Efendic
patent: 6011155 (2000-01-01), Villhauer
patent: 6107317 (2000-08-01), Villhauer
patent: 6110949 (2000-08-01), Villhauer
patent: 6124305 (2000-09-01), Villhauer
patent: 6172081 (2001-01-01), Damon
patent: 6201132 (2001-03-01), Jenkins et al.
patent: 6303661 (2001-10-01), Demuth et al.
patent: 6319893 (2001-11-01), Demuth et al.
patent: 6500804 (2002-12-01), Demuth et al.
patent: 6548481 (2003-04-01), Demuth et al.
patent: 2001/0025023 (2001-09-01), Carr
patent: 25 42 598 (1976-04-01), None
patent: 296 075 (1991-11-01), None
patent: 196 16 486 (1997-10-01), None
patent: 299 09 210 (1999-09-01), None
patent: 198 26 972 (1999-12-01), None
patent: 0 658 568 (1995-06-01), None
patent: 0 708 179 (1996-04-01), None
patent: 0 995 440 (2000-04-01), None
patent: 1 130 022 (2001-09-01), None
patent: 2 085 665 (1971-12-01), None
patent: 2 696 740 (1994-04-01), None
patent: 04-288098 (1992-10-01), None
patent: 4334357 (1992-11-01), None
patent: WO 91/11457 (1991-08-01), None
patent: WO 91/16339 (1991-10-01), None
patent: WO 91/17767 (1991-11-01), None
patent: WO 93/08259 (1993-04-01), None
patent: WO 95/11689 (1995-05-01), None
patent: WO 95/15309 (1995-06-01), None
patent: WO 95/29691 (1995-11-01), None
patent: WO 97/40832 (1997-11-01), None
patent: WO 97/45117 (1997-12-01), None
patent: WO 98/19998 (1998-05-01), None
patent: WO 98/22494 (1998-05-01), None
patent: WO 99/46272 (1999-09-01), None
patent: WO 99/61431 (1999-12-01), None
patent: WO 99/62914 (1999-12-01), None
patent: WO 00/01849 (2000-01-01), None
patent: WO 00/10549 (2000-03-01), None
patent: WO 00/53171 (2000-09-01), None
patent: WO 01/09169 (2001-02-01), None
patent: WO 01/32624 (2001-05-01), None
patent: WO 01/34594 (2001-05-01), None
patent: WO 01/62266 (2001-08-01), None
patent: WO 01/74299 (2001-10-01), None
patent: WO 01/89569 (2001-11-01), None
patent: WO 01/94310 (2001-12-01), None
patent: WO 01/97808 (2001-12-01), None
patent: WO 02/20825 (2002-03-01), None
Campbell, I.W.New Antidiabetic Drugs, ed. C.J. Bailey & P.R. Flatt, Smith-Gordon, “Sulphonylureas and metformin: efficacy and inadequacy”. 3:33-51 (1990).
Chemical Abstracts, vol. 115. No. 15, (Oct. 14, 1991) Columbus, Ohio, US; abstract No. 149947q, Schoen Ekkehard et al: “Dipeptidyl peptidase IV in the immune system. Effects of specific enzyme inhibitors on activity of dipeptidyl peptidase IV and proliferation of human lymphocytes”.
Chemical Abstracts, vol. 118, No. 25, (Jun. 21, 1993) Columbus, Ohio, US; abstract No. 255342k, Hosoda, et al, “Preparation of N-(heterocyclic Carbonyl) Amino Acids and Analogs as Prolyl Endopeptidase Inhibitors”, (Nov. 20, 1992).
Chemical Abstracts, vol. 126, No. 2, (Jan. 13, 1997) Columbus, Ohio, US; abstract No. 16161j, Stoeckel A. et al: “Competitive inhibition of proline specific enzymes by amino acid thioxopyrrolidides and thiazolidides”.
Martindale The Extra Pharmacopoeia, 30thEdition, London Pharmaceutical Press, 1993, p. 1619.
Amasheh, S., et al., “Electrophysiological analysis of the function of the mammalian renal peptide transporter expressed in Xenopus Laevis oocytes”.J. Physiol. 504, 169-174 (1997)
Arai et al., “Synthesis of prolyl endopeptidase inhibitors and evaluation of their structure-activity relationships : in vitro inhibition of prolyl endopeptidase from Canine Brain”Chemical and Pharmaceutical Bulletin., Bd. 41, No. 9, 1993, pp. 1583-1588.
Durinx, C.; et al.; “Reference Values for Plasma Dipepidyl-Pepidase IV activity and their Association with Other Laboratory Parameters”.Clin Chem Lab Med 2001, Feb.; 39 (2) :155-9, 1 page.
Gossrau, R.; “Cytochemistry of Membrane Proteases”.Histochem J, Jul. 1985; 17 (7) :737-771, 1 page.
Hahn, T.; et al.; “Enzyme Histochemical Evidence for the Presence of Potential Blood Pressure Regulating Proteases in Cultured Villous Explants from Human First Trimester Placentae”.Acta HistochemDec. 1993, 95 (2) :185-92, 1 page.
Heymann, E. et al., “Has Dipeptidyl Peptidase IV an Effect on Blood Pressure and Coagulation.”Klin Wochenschr, Jan. 1984, 2;62 (1) :2-10, 1 page.
Lin, J. et al.: “Inhibition of depeptidyl peptidase IV by fluoroolefin-containing n-peptidyl-O-hydroxylamine peptidomimetics”Proceedings of the National Academy of Sciences of USA, vol. 95, Nov. 1998, pp. 14020-14024.
Korom, S., et al “Inhibition of CD26/dipeptidyl peptidase IV activity in vivo prolongs cardiac allograft survival in rat recipients”,Transplantation, vol. 63, 1495-1500 No. 10 (1997).
Magyar, C.E. et al., “Proximal Tubule Na Transporter Responses are the same during Acute and Chronic Hypertension.”Am J. Physiol Renal Physiol, Aug. 2000; 279 (2) :F358-69, 1 page.
Martindale The Extra Pharmacopoeia, 30thEdition, London Pharmaceutical Press, 1993, p. 36.
Mentlein, R., et al., “Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV”.Regul. Pept.49, 133-144 (1993).
Papies, B. et al., “Isoenzyme (Lactate Dehydrogenase, Aspartate Aminotransferase) and Dipeptidyl Peptidase IV Activity Changes in Blood Plasma Likely Indicative of Organ Involvement due to Arterial Hypertension.”Cor Vasa, 1991; 33 (3) :218-26, 1 page.
Qureshi, N.U.; et al., “Endogenous Neuropeptide Y Mediates Vasoconstriction during Endotoxic and Hemorrhagic Shock”.Regul Pept, Sep. 25, 1998; 75-76:215-20, 1 page.
Tanka, S., et al., “Suppression of arthritis by the inhibitors of dipeptidyl peptidase IV”.Int. J. Immunopharmacol, vol. 19, No. 1 pp. 15-24, (1997).
The Merck Index, 11thEdition,An Encyclopedia of Chemicals, Drugs, and Biologicals, 1989, p. 934.
The Merck Index, 12thEdition,An Encyclopedia of Chemicals, Drugs, and Biologicals, 1996, p. 1014.
Deacon et al.,Journal of Clinical Endocrinology and Metabolism, “Degradation of Glucagon-Like Peptide-1 by Human Plasma in Vitro Yields and N-Terminally Truncated Peptide That Is a Major Endogenous Metabolite in Vivo”, (1995), 80(3): 952-957.
G.G. Duncan,Diseases of Metabolism(Asian edition), “Diabetes Mellitus”, (1966), p. 951-957.
Gutniak et al.,Diabetes Care, “Subcutaneous Injection of the Incretin Hormone Glucagon-Like Peptide 1 Abolishes Postprandial Glycemia in NIDDM”, Sep. 1994, 17(9): 1039-1044.
Gutniak et al.,New England Journal of Medicine, “Antidiabetogenic Effect of Glucagon-like peptide-1 (7-36) Amide in Normal Subjects and Patients With Diabetes Mellitus”, 1992, 326: 1316-1322.
H.A. Smith et al.,Veterinary Pathology(fourth edition), “Diseases and Disorders of Metabolism: Deficiency Diseases”, (1972), p. 1018-1020.
Hendrick et al.,Metabolism—Clinical and Experimental, “Glucagon-like Peptide-I-(7-37) Suppresses Hyperglycemia in Rats”, Jan. 1993, 42(1): 1-6.
Hoffmann et al.,Journal of Chromatography A, “Inhibition of dipeptidyl peptidase IV (DP IV) by anti-DP IV antibodies and non-subs

Affiliated with

Also associated with

Rating

Prodrugs of DP IV-inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Prodrugs of DP IV-inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prodrugs of DP IV-inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3754216